Organon & Co. (OGN)

$8.43 +0.31 (3.82%)
Market Cap 2.11B
Revenue (ttm) 6.40B
Net Income (ttm) 864.00M
EPS (ttm) N/A
PE Ratio 2.21
Forward PE 2.15
Profit Margin 13.49%
Debt to Equity Ratio 9.74
Volume 8,350,800
Avg Vol 5,679,996
Day's Range N/A - N/A
Shares Out 259.98M
Stochastic %K 91%
Beta 0.58
Analysts Hold
Price Target $9.93

Company Profile

Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 551 430 6900
Address:
30 Hudson Street, Floor 33, Jersey City, United States
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Jan. 13 at 8:18 AM
$OGN When Jerome Powell get replaced w/ a puppet chair, the bear case for Organon is dead. Here is the playbook for 2026: 1. The Debt Catalyst 📉 Lower rates = easy refinancing. The "bankruptcy risk" currently priced into the stock evaporates immediately. Shorts counting on high rates to crush them will get squeezed. 2. The Weak Dollar Super-Cycle 💵 "Fear in the Dollar" is the ultimate tailwind here. ~80% of revenue is Ex-US. Strong Dollar = Crushed OGN earnings (2023-2025). Weak Dollar = Massive "on paper" EPS beat without selling a single extra pill. 3. Valuation Re-Rating 📊 Currently trading at ~2.3x P/E (Zombie valuation). With rate cuts + currency boost, we just need a modest re-rate to 6x P/E to see a triple. Prediction: Market realizes this is the ultimate "Safe Haven + Yield" play. EOY Target: $18 - $24 (Re-rating + Short Squeeze). Don't ignore the FX impact. This is the sleeper trade of the year. 🐂
0 · Reply
TSLA_S3XY
TSLA_S3XY Jan. 13 at 3:32 AM
Of All US Listed Biotechnology & BIOPHARMA Companies There Are Only 2 That Have A Trailing PE Less Than 4 & 200m+ Revenue $OGN & $CRMD We Picked A Real Winner.
1 · Reply
handmedown1
handmedown1 Jan. 9 at 5:27 PM
$OGN im guess 8 options
0 · Reply
JohnWealthcraft
JohnWealthcraft Jan. 8 at 7:02 PM
$OGN
0 · Reply
handmedown1
handmedown1 Jan. 8 at 1:27 PM
$OGN unreal
0 · Reply
WallStJesus
WallStJesus Jan. 7 at 2:48 PM
$OGN Put/Call: 85/4978
0 · Reply
Value1996
Value1996 Jan. 6 at 11:28 PM
$OGN
0 · Reply
handmedown1
handmedown1 Jan. 6 at 7:59 PM
$OGN $SLS another one with a buyout
0 · Reply
handmedown1
handmedown1 Jan. 6 at 4:04 PM
$OGN buyout for 15
1 · Reply
bingy329
bingy329 Jan. 5 at 9:17 PM
$OGN large call buyer came after the buyout article: "Samsung Bioepis pursues direct sales and reviews Organon acquisition to boost revenue - CHOSUNBIZ" I grabbed some calls, but not expecting this to pan out. Samsung denied the report.
0 · Reply
Latest News on OGN
Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Jan 8, 2026, 1:30 AM EST - 6 days ago

Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Dec 3, 2025, 12:23 PM EST - 6 weeks ago

Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 7:30 AM EST - 7 weeks ago

Organon To Present at the Piper Sandler 37th Annual Healthcare Conference

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Nov 17, 2025, 5:30 AM EST - 2 months ago

Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Nov 11, 2025, 12:58 PM EST - 2 months ago

Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect

Organon Analysts Cut Their Forecasts Following Q3 Results

Nov 11, 2025, 11:40 AM EST - 2 months ago

Organon Analysts Cut Their Forecasts Following Q3 Results

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:51 AM EST - 2 months ago

Organon & Co. (OGN) Q3 2025 Earnings Call Transcript

Organon Reports Results for the Third Quarter Ended September 30, 2025

Nov 10, 2025, 7:30 AM EST - 2 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2025

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Nov 7, 2025, 7:30 AM EST - 2 months ago

Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

Nov 6, 2025, 7:30 AM EST - 2 months ago

Organon To Report Third Quarter 2025 Results and Host Conference Call on November 10, 2025

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Oct 28, 2025, 2:06 PM EDT - 2 months ago

The Bottom Fishing Club - Organon: Deep Value In Drugs/Medical Products

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Oct 27, 2025, 6:22 PM EDT - 2 months ago

Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper Wholesale Sales Practices, Abrupt CEO Departure -- Hagens Berman

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Oct 27, 2025, 7:44 AM EDT - 2 months ago

Organon CEO Kevin Ali to resign after probe into wholesaler sales practices

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Oct 27, 2025, 7:30 AM EDT - 2 months ago

Organon Appoints Company Executive Joseph Morrissey as Interim CEO and Board Chair Carrie Cox as Executive Chair; Announces Results of Audit Committee Investigation

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

Oct 17, 2025, 7:10 AM EDT - 3 months ago

Organon: Muted H2 2025 Ahead, But Distressed Valuation And Manageable Debt Makes It A Compelling Buy

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 19, 2025, 6:00 AM EDT - 4 months ago

European Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Sep 2, 2025, 5:30 AM EDT - 4 months ago

US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively

Organon: Valuation Discount Offset By Structural Headwinds

Aug 12, 2025, 2:22 PM EDT - 5 months ago

Organon: Valuation Discount Offset By Structural Headwinds

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Aug 6, 2025, 11:59 AM EDT - 5 months ago

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade)

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Aug 5, 2025, 1:10 PM EDT - 5 months ago

Organon & Co. (OGN) Q2 2025 Earnings Call Transcript

Organon Reports Results for the Second Quarter Ended June 30, 2025

Aug 5, 2025, 7:30 AM EDT - 5 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2025

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

Jul 22, 2025, 7:30 AM EDT - 6 months ago

Organon To Report Second Quarter 2025 Results and Host Conference Call on August 5, 2025

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

Jul 21, 2025, 4:02 PM EDT - 6 months ago

OGN Shareholders Have the Right to Lead the Organon & Co. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - OGN

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 20, 2025, 10:55 AM EDT - 6 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 11, 2025, 9:37 AM EDT - 6 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Jul 10, 2025, 8:18 AM EDT - 6 months ago

OGN COURT NOTICE: Organon & Co. Investors may have been Affected by Fraud – Contact BFA Law by the July 22 Legal Deadline (NYSE:OGN)

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

Jul 8, 2025, 1:14 PM EDT - 6 months ago

Trade Tracker: Jenny Harrington sells Organon and buys Vici Properties

VICI

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

Jul 7, 2025, 7:30 AM EDT - 6 months ago

Organon's VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the American Academy of Dermatology Updated 2025 Guidelines for Adult Atopic Dermatitis

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Jul 3, 2025, 8:25 AM EDT - 6 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon

Karolinska Development receives update from Organon concerning OG-6219

Jul 3, 2025, 1:00 AM EDT - 6 months ago

Karolinska Development receives update from Organon concerning OG-6219

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Jul 2, 2025, 8:01 AM EDT - 7 months ago

Organon to halt development of endometriosis pain drug after mid-stage trial failure

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

Jul 2, 2025, 7:30 AM EDT - 7 months ago

Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 28, 2025, 7:46 AM EDT - 7 months ago

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

Jun 26, 2025, 9:00 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon Lawsuit - OGN

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

Jun 23, 2025, 9:00 AM EDT - 7 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 22, 2025 in Organon & Co. Lawsuit - OGN

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

Jun 20, 2025, 9:06 AM EDT - 7 months ago

OGN COURT REMINDER: Organon & Co. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Jun 18, 2025, 8:38 AM EDT - 7 months ago

OGN NOTICE: Did Organon & Co. Mislead Investors? Contact BFA Law by July 22 Court Deadline if You Suffered Losses (NYSE:OGN)

Organon: A Look Beyond The Dividend Cut

Jun 18, 2025, 1:02 AM EDT - 7 months ago

Organon: A Look Beyond The Dividend Cut

BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Jan. 13 at 8:18 AM
$OGN When Jerome Powell get replaced w/ a puppet chair, the bear case for Organon is dead. Here is the playbook for 2026: 1. The Debt Catalyst 📉 Lower rates = easy refinancing. The "bankruptcy risk" currently priced into the stock evaporates immediately. Shorts counting on high rates to crush them will get squeezed. 2. The Weak Dollar Super-Cycle 💵 "Fear in the Dollar" is the ultimate tailwind here. ~80% of revenue is Ex-US. Strong Dollar = Crushed OGN earnings (2023-2025). Weak Dollar = Massive "on paper" EPS beat without selling a single extra pill. 3. Valuation Re-Rating 📊 Currently trading at ~2.3x P/E (Zombie valuation). With rate cuts + currency boost, we just need a modest re-rate to 6x P/E to see a triple. Prediction: Market realizes this is the ultimate "Safe Haven + Yield" play. EOY Target: $18 - $24 (Re-rating + Short Squeeze). Don't ignore the FX impact. This is the sleeper trade of the year. 🐂
0 · Reply
TSLA_S3XY
TSLA_S3XY Jan. 13 at 3:32 AM
Of All US Listed Biotechnology & BIOPHARMA Companies There Are Only 2 That Have A Trailing PE Less Than 4 & 200m+ Revenue $OGN & $CRMD We Picked A Real Winner.
1 · Reply
handmedown1
handmedown1 Jan. 9 at 5:27 PM
$OGN im guess 8 options
0 · Reply
JohnWealthcraft
JohnWealthcraft Jan. 8 at 7:02 PM
$OGN
0 · Reply
handmedown1
handmedown1 Jan. 8 at 1:27 PM
$OGN unreal
0 · Reply
WallStJesus
WallStJesus Jan. 7 at 2:48 PM
$OGN Put/Call: 85/4978
0 · Reply
Value1996
Value1996 Jan. 6 at 11:28 PM
$OGN
0 · Reply
handmedown1
handmedown1 Jan. 6 at 7:59 PM
$OGN $SLS another one with a buyout
0 · Reply
handmedown1
handmedown1 Jan. 6 at 4:04 PM
$OGN buyout for 15
1 · Reply
bingy329
bingy329 Jan. 5 at 9:17 PM
$OGN large call buyer came after the buyout article: "Samsung Bioepis pursues direct sales and reviews Organon acquisition to boost revenue - CHOSUNBIZ" I grabbed some calls, but not expecting this to pan out. Samsung denied the report.
0 · Reply
RonIsWrong
RonIsWrong Jan. 5 at 7:47 PM
$OGN Unusual Options Activity volume spike started due to the 6000 Feb $8 calls that were bought at 1:34. Market maker delta positioning typically requires buying shares to offset the calls sold there. more than 10,000 now on the Feb $8 along with some March $9 calls.
0 · Reply
twofortwo
twofortwo Jan. 5 at 6:56 PM
$OGN spiking still early
0 · Reply
twofortwo
twofortwo Jan. 5 at 6:55 PM
$OGN about to run to 10 by eod
0 · Reply
frankster
frankster Jan. 5 at 6:47 PM
$OGN probably new CEO announcement! Of course i had to sell my 20000 shares for tax loss. 😠😠
0 · Reply
BOBJOSCAUWBERGH
BOBJOSCAUWBERGH Jan. 5 at 6:44 PM
$OGN news?
1 · Reply
_TP888
_TP888 Jan. 5 at 6:38 PM
$OGN Unusual Calls being bought on this spike
0 · Reply
WallStJesus
WallStJesus Jan. 5 at 6:36 PM
$OGN UNUSUAL SPEC BUYING
1 · Reply
c0ffee
c0ffee Jan. 5 at 2:38 AM
$OGN end of year tax loss selling over.
0 · Reply
yourit
yourit Jan. 2 at 2:15 AM
$WEN $OGN $NWL Witch one should be the heaviest weight in my IRA
3 · Reply
mdes
mdes Dec. 28 at 6:59 PM
$OGN brutal year for Organon bahholders.. even scalping did not work.. cannot keep loading new capital at lower levels.. (among various spinoffs Solventum was one winner)
2 · Reply
TeamBullish
TeamBullish Dec. 17 at 4:23 PM
I’m not going to waste your time forcing a trigger that doesn’t offer real value. I’ve been conducting analysis across the current landscape, and the opportunity just isn’t there right now. Capital stays reserved and ready to deploy when probability is actually on our side. Yes, there are penny scalps floating around if that’s your style, but that’s not what we’re here for. I haven’t taken a single trade today, and I’m completely fine with that. No frustration, no urgency. This is a long game. Always has been. The edge comes from patience and from choosing our spots with precision. When the conditions line up, we’ll act. Until then, stay calm and stay disciplined. $VYNE $YCBD $OGN $ATPC $DRCT
2 · Reply
An1i_James
An1i_James Dec. 16 at 4:40 PM
$OGN SBFM buyers quietly loading while timeline sleeps 👀
1 · Reply